RxDoctor Payments Data

Andrea Gallo

Optometrist · Wilmington, DENPI 1114284544

Payments from drug & device makers

$546in general payments, 2019–2025

Across 17 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dompe US, Inc.$209
  • Tarsus Pharmaceuticals, Inc.$95
  • Novartis$65
  • AbbVie$65
  • Oyster Point Pharma, Inc.$45
  • Sun Pharmaceutical Industries Inc.$34
  • plus $33 from 1 others

What the payments were for

  • Food & beverage$546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$546 in reported general payments places this provider in the 35th percentile of 146 optometrist providers in Delaware.

See all optometrist providers in Delaware

Medicare billing

Part B allowed, 2024
$71,300
Medicare patients
283
Services billed
859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast70$103,652
XdemvyLotilaner46$87,191
RestasisCyclosporine82$67,194
LumiganBimatoprost67$41,428
TyrvayaVarenicline Tartrate28$23,233
MieboPerfluorohexyloctane/Pf28$20,957
Cyclosporine23$8,621
ZerviateCetirizine Hcl20$7,611
SimbrinzaBrinzolamide/Brimonidine Tart20$4,027
Brimonidine Tartrate40$3,815
Azelastine Hcl36$1,152
ErythromycinErythromycin Base93$772
Prednisolone Acetate14$755
Latanoprost42$417
Dorzolamide Hcl14$226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$65$108,621149 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$95$87,19146 claims
Oyster Point Pharma, Inc.Tyrvaya$45$23,23328 claims
AlconSimbrinza$33$4,02720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 146 optometrist providers in Delaware.

Other optometrist in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →